Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.41 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.41 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773105 | 0.86 | CFTR (0.52) | NAMPTCYP2C9CFTRKMT2A | |
| SCHEMBL28203528 | 0.86 | CFTR (0.52) | NAMPTCYP2C9CFTRKMT2A | |
| SCHEMBL15530698 | 0.84 | NAMPT (0.51) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15231982 | 0.82 | NAMPT (0.56) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15530395 | 0.81 | KMT2A (0.55) | NAMPTCYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL16820411 | 0.80 | HTR2A (0.55) | NAMPTKMT2AABCC9ABCC8KCNJ11 | |
| SCHEMBL29642709 | 0.77 | CFTR (0.53) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19666968 | 0.77 | CFTR (0.53) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15530613 | 0.76 | KMT2A (0.57) | NAMPTCYP2C9SLC40A1KMT2AABCC9 | |
| SCHEMBL15530287 | 0.76 | KMT2A (0.42) | FBP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | claimed |
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | VALO EARLY DISCOVERY, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9458172-B2 | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives | VALO HEALTH, INC. | 2016-10-04 | — | — | US | disclosed |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | Valo Health, LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885CYP3A4 598/4885CYP2D6 264/4885 |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885CYP3A4 598/4885CYP2D6 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.